News Releases

September 12, 2001

Dainippon and Schering-Plough K.K. Concluded a Co-Marketing Agreement Regarding the Anti-Asthmatic Product, "QVAR™"

September 12, 2001 --- Dainippon Pharmaceutical Co. Ltd. ("Dainippon", President: Kenjiro Miyatake) and Schering-Plough K.K. ("SPKK", President: Masao Torii) jointly announced today that they signed a co-marketing agreement for a new metered-dose inhaler (MDI) of beclomethasone dipropionate (BDP). Under the terms of this agreement, the two companies will co-market the anti-asthmatic product under the trade name of "QVAR™" in Japan.

MDIs of BDP have been widely used as a maintenance therapy for asthma. QVAR™ uses a chlorofluorocarbon-free (CFC-free) propellant HFA-134a, which has no ozone-depletion potential. Incorporating many advances in drug delivery technology, QVAR™ is expected to require only half the dose of the currently available MDIs of BDP to achieve the same efficacy.

QVAR™ has already been launched in 25 countries including the U.K. and the U.S. In Japan, Dainippon has the development and marketing rights as granted by its originator, 3M Pharmaceuticals (Division Vice President: Thomas B. Harrison, Head Office: St. Paul, Minnesota), which is the Pharmaceutical Business Division of Minnesota Mining and Manufacturing Company. Dainippon has developed QVAR™ in Japan for the treatment of asthma and has filed its registration application with the Japanese Ministry of Health, Labor and Welfare.

Dainippon considers QVAR™ an important product to expand its share in the respiratory disease market when combined with the sales of "AIROMIR™" (CFC-free MDI of salbutamol sulfate), a product which was also licensed from 3M Pharmaceuticals and has been marketed by Dainippon in Japan since 1997. SPKK enjoys a well-established position in the respiratory disease market, and further strengthens its product pipeline in the therapeutic area with the conclusion of t his agreement.

Dainippon and SPKK expect this collaboration to strengthen their market position and allow for the rapid market penetration of QVAR™. Both companies consider that this co-marketing arrangement will not only contribute towards improving the treatment of asthma but also towards ozone layer protection as well.